[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Fulkerson et al., 2013 - Google Patents

Targeting eosinophils in allergy, inflammation and beyond

Fulkerson et al., 2013

View HTML
Document ID
13919945472927274444
Author
Fulkerson P
Rothenberg M
Publication year
Publication venue
Nature reviews Drug discovery

External Links

Snippet

Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Similar Documents

Publication Publication Date Title
Fulkerson et al. Targeting eosinophils in allergy, inflammation and beyond
Porsbjerg et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
Schadler et al. Biologics for the primary care physician: Review and treatment of psoriasis
Huangfu et al. The IL-17 family in diseases: from bench to bedside
Barnes Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Gandhi et al. Targeting key proximal drivers of type 2 inflammation in disease
Chen et al. Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma
Wegmann Targeting eosinophil biology in asthma therapy
Brightling et al. Interleukin‐13: prospects for new treatments
Mannon et al. Republished: Interleukin 13 and its role in gut defence and inflammation
Ingram et al. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies
Lilly et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids.
Cho Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic
Holgate Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?
Manni et al. The complex relationship between inflammation and lung function in severe asthma
Karras et al. Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice
Caramori et al. New drugs targeting Th2 lymphocytes in asthma
Hodsman et al. A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics
US20210386855A1 (en) Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP2627673B1 (en) Therapies for improving pulmonary function
Ji et al. T-helper cells and their cytokines in pathogenesis and treatment of asthma
Catherine et al. What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?
Wedemeyer et al. Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa
Máspero Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects
Nguyen et al. Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β2-adrenoceptor overexpression